Trust signals
> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial
Key Takeaways
- Retatrutide is investigational and not FDA-approved as of May 2026. FormBlends does not sell, supply, or formulate retatrutide. This page is educational.
- Phase 2 weight loss at 12 mg weekly: mean 24.2% over 48 weeks, the largest figure ever reported in an obesity drug trial. The weight curve had not plateaued at trial end.
- Phase 2 diabetes data: HbA1c reductions of about 1.6 to 2.0 percentage points at higher doses over 36 weeks.
- The most distinctive finding: dramatic reductions in liver fat content (over 80% relative reduction in imaging substudies), larger than what is seen with semaglutide or tirzepatide.
- Effects come with costs: heavy gastrointestinal side effect burden, modest heart rate increase, and a discontinuation rate at the maximum dose of about 16% in phase 2.
Direct answer
In published phase 2 trials, retatrutide produced large weight loss (about 24% of body weight at 48 weeks at the highest dose), strong glucose control improvements in patients with type 2 diabetes, substantial reductions in liver fat, modest decreases in blood pressure, and reduced waist circumference. It also produced significant gastrointestinal side effects in most participants and a modest heart rate increase. The phase 2 data is the most ambitious published efficacy profile of any obesity drug to date, but the trial was short (48 weeks) and small (338 participants), and the drug is not yet FDA-approved.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- What "what does it do" actually requires answering
- The weight loss number, with full context
- The weight loss curve over time
- Glucose effects in non-diabetic and diabetic populations
- The liver fat finding (the most distinctive piece)
- Body composition: fat versus lean mass
- Blood pressure and waist circumference
- Effects on appetite and food relationship (the patient-reported piece)
- What retatrutide does that it shouldn't (side effects as effects)
- How effects translate from trial to real world
- The contrary view: are the phase 2 numbers durable?
- FAQ
- Sources
What "what does it do" actually requires answering
The honest answer to "what does retatrutide do" has to cover four domains:
- Weight effects. How much, how fast, and how durably?
- Metabolic effects. Glucose, lipids, blood pressure, liver fat.
- Body composition effects. Where does the weight come from?
- Patient-experience effects. What does it feel like to take?
And it has to acknowledge what the data does not cover: long-term outcomes, cardiovascular event rates, mortality, cancer rates, real-world adherence, comparative effectiveness against tirzepatide head-to-head. None of these are characterized for retatrutide as of May 2026.
The weight loss number, with full context
The phase 2 trial (Jastreboff AM et al., NEJM June 2023) enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity. Randomization was to placebo or one of four retatrutide doses (1, 4, 8, or 12 mg weekly). Treatment lasted 48 weeks.
| Dose arm | Mean weight loss at 48 weeks | Participants achieving ≥15% loss | Participants achieving ≥25% loss |
|---|---|---|---|
| Placebo | ~2.1% | ~0% | ~0% |
| Retatrutide 1 mg | ~8.7% | ~13% | ~2% |
| Retatrutide 4 mg | ~17.1% | ~52% | ~24% |
| Retatrutide 8 mg | ~22.8% | ~74% | ~48% |
| Retatrutide 12 mg | ~24.2% | ~83% | ~48% |
The reference points for the 24.2% figure:
- STEP 1 semaglutide 2.4 mg: ~14.9% at 68 weeks
- SURMOUNT-1 tirzepatide 15 mg: ~22.5% at 72 weeks
- Bariatric surgery (gastric sleeve): ~25-30% sustained at one year
- Bariatric surgery (gastric bypass): ~30-35% sustained at one year
The retatrutide phase 2 result is the first non-surgical obesity treatment to approach surgical magnitudes of weight loss. That framing is what made the trial a headline event in June 2023.
The weight loss curve over time
The shape of the weight loss curve matters as much as the endpoint. Here is the rough trajectory:
| Time point | Mean weight loss (12 mg arm) |
|---|---|
| Week 4 | ~3% |
| Week 12 | ~10% |
| Week 24 | ~16% |
| Week 36 | ~21% |
| Week 48 | ~24.2% |
Three observations stand out:
First, weight loss is gradual. Roughly 0.5% body weight per week on average during the active loss phase. That matches the slower, more sustainable pattern seen with other incretins, not the rapid drops seen with severe caloric restriction or surgical interventions.
Second, the curve had not plateaued at 48 weeks. Participants in the higher-dose arms were still losing weight when the trial ended. This is unusual. Most obesity drug curves plateau by week 36-48. Retatrutide's continued slope suggests longer trials may show even larger weight loss.
Third, the dose-response relationship is clear. Higher doses produced larger weight loss with reasonable linearity through 8 mg, then a smaller increment from 8 mg to 12 mg. This pattern suggests the 8-12 mg range is the meaningful efficacy zone, with the 12 mg dose offering modest additional benefit at higher side effect cost.
Glucose effects in non-diabetic and diabetic populations
The phase 2 obesity trial enrolled participants without diabetes, so glucose effects there were modest by design. The phase 2 diabetes trial (Rosenstock J et al., Lancet 2023) is the better reference point for glycemic effects.
In adults with type 2 diabetes treated for 36 weeks:
- HbA1c reduction at 12 mg: approximately 2.0 percentage points
- HbA1c reduction at 8 mg: approximately 1.6 percentage points
- HbA1c reduction at 4 mg: approximately 1.3 percentage points
- Placebo: minimal change
For comparison, tirzepatide in SURPASS-2 (a 40-week head-to-head against semaglutide 1 mg in T2D) showed HbA1c reductions of approximately 2.3 percentage points at 15 mg. Retatrutide's glycemic effect is in the same neighborhood as tirzepatide's, although the trials are not directly comparable.
A meaningful percentage of trial participants with diabetes achieved HbA1c below 5.7% (the normal range threshold) at the higher retatrutide doses, indicating diabetes remission in the trial window. Whether remission persists with continued treatment, and what happens with treatment discontinuation, remains to be characterized in phase 3.
The liver fat finding (the most distinctive piece)
The phase 2 obesity trial included an imaging substudy measuring liver fat content via MRI-PDFF (magnetic resonance imaging proton density fat fraction). The results were striking.
| Dose arm | Mean relative reduction in liver fat at 48 weeks |
|---|---|
| Placebo | ~0% |
| Retatrutide 4 mg | ~57% |
| Retatrutide 8 mg | ~81% |
| Retatrutide 12 mg | ~82% |
A large fraction of participants at higher doses achieved liver fat content below 5%, the threshold below which hepatic steatosis is not diagnosable. Many of these patients started with significant steatosis at baseline.
The clinical relevance: metabolic-associated fatty liver disease (MAFLD) affects roughly 25-30% of adults globally and is the leading cause of chronic liver disease. A drug that reduces hepatic fat by 80% in less than a year would be a substantial therapeutic advance. Whether this translates to reduced rates of fibrosis progression, cirrhosis, or hepatocellular carcinoma will require dedicated long-term studies.
The mechanism explanation: glucagon receptor activation increases hepatic fatty acid oxidation. The liver shifts from fat-storage mode to fat-burning mode. Tirzepatide and semaglutide both reduce liver fat (via weight loss and possibly direct hepatic effects), but neither produces reductions of this magnitude in the same trial duration.
Body composition: fat versus lean mass
DEXA (dual-energy X-ray absorptiometry) substudies in phase 2 examined what tissue compartments the weight loss came from. Selected findings:
- Approximately 80% of total weight lost at higher doses was fat mass
- Approximately 20% was lean mass
- Visceral fat (abdominal organ-associated fat) loss was proportionally larger than subcutaneous fat loss
- Bone mineral density was preserved over 48 weeks
The 80/20 split is favorable. For context, surgical weight loss typically produces 70-75% fat to 25-30% lean. Pure caloric restriction produces less favorable ratios, often closer to 70/30. Retatrutide's body composition profile is therefore better than diet alone and competitive with tirzepatide and bariatric surgery.
The implication for muscle preservation: the lean mass loss is real but relatively small in proportion. Resistance training during treatment would likely improve the ratio further, although direct trial evidence for resistance training in retatrutide-treated patients does not exist.
Blood pressure and waist circumference
Systolic blood pressure. Mean reductions of approximately 7-9 mmHg at higher doses over 48 weeks. The magnitude is consistent with what is observed with significant weight loss in general, plus possible direct GLP-1 effects on vascular tone. For patients with hypertension, the reduction is clinically meaningful.
Diastolic blood pressure. Smaller reductions, approximately 2-4 mmHg.
Waist circumference. Mean reductions of approximately 17 cm at the highest dose over 48 weeks. The reduction is proportional to fat mass loss and reflects substantial visceral adipose tissue reduction.
Lipid panel. Triglycerides decreased substantially. LDL cholesterol showed modest decreases. HDL cholesterol showed small increases. The pattern matches what is observed with tirzepatide.
Effects on appetite and food relationship (the patient-reported piece)
Beyond the trial numbers, the experiential effects are worth noting. The phase 2 trial collected patient-reported outcomes:
- Reduced hunger ratings, scaling with dose
- Reduced cravings for high-calorie foods
- Reduced food preoccupation ("food noise")
- Earlier satiety during meals
- Reduced enjoyment of food in some participants (sometimes reported as a downside)
The pattern matches what patients on semaglutide and tirzepatide describe. The intensity may be greater with retatrutide, but this has not been directly compared.
Some participants reported that the appetite reduction was so significant that they had to set reminders to eat. This is a known challenge with high-dose incretins and a reason that dietary counseling is recommended alongside pharmacotherapy.
What retatrutide does that it shouldn't (side effects as effects)
"What does retatrutide do" cannot omit the things it does that you might not want.
Gastrointestinal effects. Nausea, diarrhea, vomiting, constipation, decreased appetite. At the 12 mg dose, about 75% of participants experienced nausea at some point.
Heart rate elevation. Mean increase of approximately 6 bpm at the highest dose. Larger than semaglutide or tirzepatide.
Skin reactions. Injection site reactions (redness, itching) at modest rates similar to other once-weekly injectables.
Fatigue. Reported in a meaningful minority of participants, particularly during titration.
Discontinuation. About 16% of participants on the highest dose discontinued due to side effects.
The "what does it do" question has to include these. They are part of the drug's effect profile, not separate footnotes.
How effects translate from trial to real world
Trial averages are not predictions for individual patients. Several factors affect how retatrutide effects would translate to real-world clinical use:
- Adherence. Trial participants were monitored and motivated. Real-world adherence to weekly injectables is typically 60-70% at one year per pharmacy claims data. Lower adherence means smaller real-world weight loss.
- Dose tolerance. Many real-world patients will not reach the 12 mg dose due to GI intolerance. If the average tolerated maintenance dose is 6-8 mg, average real-world weight loss would be closer to 17-22%.
- Concurrent lifestyle changes. Trial protocols typically include diet and physical activity counseling. Real-world prescribing varies widely in lifestyle support.
- Baseline differences. Trial participants had specific BMI ranges (≥27 with comorbidity or ≥30). Real-world patients with different starting BMIs may respond differently.
- Concurrent medications. Trial exclusion criteria removed certain medication users. Real-world patients on diverse polypharmacy may have different effect profiles.
A reasonable real-world weight loss expectation, if retatrutide is approved and used at typical maintenance doses, would be in the range of 15-22% over the first year for adherent patients. The 24% trial figure is a ceiling, not an expectation.
The contrary view: are the phase 2 numbers durable?
The phase 2 results are striking, but pharma history is full of phase 2 results that shrank in phase 3 or in real-world use. Two concerns:
Concern 1: Phase 2 to phase 3 effect-size attenuation. Larger, more diverse populations typically show somewhat smaller effects than tightly controlled phase 2 cohorts. Tirzepatide held up well in this transition. Retatrutide may or may not. If phase 3 shows mean weight loss of 19-22% instead of 24%, the drug remains exceptional. If it shows 15-18%, the comparative advantage over tirzepatide narrows substantially.
Concern 2: Real-world weight regain after discontinuation. The STEP 1 extension and SURMOUNT-4 data show that incretin-induced weight loss is largely contingent on continued use. Withdrawal trials for retatrutide have not been published. If withdrawal produces the same rapid regain seen with other incretins, retatrutide becomes a lifetime therapy in practice, not a short-term intervention.
Concern 3: Tolerability ceiling. If most real-world patients cannot tolerate the maximum dose, the average effect in clinical use will be smaller than the 24% headline. The 16% discontinuation rate at 12 mg in phase 2 is a real signal that real-world dose ceilings may be lower than the trial maximum.
The honest synthesis: retatrutide's phase 2 effects are impressive. They are also preliminary, observed in a small sample over a short duration in a controlled setting. The drug remains promising but not proven.
FAQ
What does retatrutide do? It produces weight loss (about 24% at the highest dose over 48 weeks in phase 2), improves glucose control, reduces liver fat substantially, lowers blood pressure modestly, and reduces waist circumference. It also produces GI side effects and modest heart rate increase. It is investigational and not FDA-approved.
How much weight loss does retatrutide cause? Phase 2 mean weight loss was about 24.2% at 12 mg weekly over 48 weeks. Individual results varied widely. About 83% of participants at the highest dose lost at least 15% of body weight.
Does retatrutide help with diabetes? Yes. Phase 2 diabetes data showed HbA1c reductions of about 1.6 to 2.0 percentage points at higher doses over 36 weeks.
Does retatrutide reduce liver fat? Yes, substantially. Imaging substudies showed about 80% relative reduction in liver fat at higher doses over 48 weeks.
Does retatrutide affect blood pressure? Mean systolic blood pressure reductions of about 7-9 mmHg at higher doses. Consistent with significant weight loss.
What does retatrutide do to muscle? Lean mass loss is roughly 20% of total weight lost, with 80% from fat mass. Lean mass preservation is comparable to or somewhat better than tirzepatide.
How fast does retatrutide work? Weight loss begins in the first weeks and accelerates over months. Phase 2 weight loss had not plateaued at 48 weeks.
Does retatrutide affect cholesterol? Triglycerides decrease substantially. LDL shows modest decreases. HDL shows small increases.
Does retatrutide make people feel different? Patients report reduced hunger, reduced food cravings, and earlier satiety. Some describe reduced enjoyment of food. Some experience fatigue, particularly during titration.
Will retatrutide effects continue forever? Continued treatment is likely required to maintain weight loss. Withdrawal data has not been published. Other incretins show substantial weight regain after discontinuation.
What does retatrutide do to insulin sensitivity? Phase 2 data showed improvements in insulin sensitivity markers, consistent with weight loss plus the GIP/GLP-1 mechanism.
What does retatrutide do for liver disease? Beyond reducing liver fat, dedicated phase 3 trials are evaluating effects on metabolic-associated steatohepatitis (MASH) and fibrosis. Final efficacy data are pending.
Related guides
- Does Retatrutide Cause Diarrhea? The Phase 2 Numbers in Context
- Does Retatrutide Cause Hair Loss? A Look at the Phase 2 Data and the Mechanism
- Does Retatrutide Need to Be Refrigerated? A Direct Answer
- Retatrutide and Male Fertility: A Closer Look at What the Evidence Actually Shows
- Does Retatrutide Show Up on a Drug Test? What Standard Panels Actually Look For
- Is Retatrutide Safe? An Honest Read of the Phase 2 Data
Sources
- Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. June 2023.
- Rosenstock J et al. Retatrutide for type 2 diabetes: a phase 2 trial. Lancet. 2023.
- Sanyal AJ et al. Effect of retatrutide on liver fat: Substudy results from the Phase 2 obesity trial. Nature Medicine. 2024.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance: The STEP 4 Trial. JAMA. 2021.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). New England Journal of Medicine. 2023.
- Coskun T et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metabolism. 2022.
- Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
- American Association of Clinical Endocrinologists. Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. 2024 update.
- Endocrine Society. Clinical Guidance on Investigational Incretin Therapies. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends operates as a digital health platform connecting patients with independent licensed clinicians and state-licensed compounding pharmacies. We do not manufacture, prescribe, or dispense medication directly. FormBlends does not sell, supply, or formulate retatrutide. Retatrutide is investigational and not FDA-approved.
Compounded Medication Notice. Compounded semaglutide and compounded tirzepatide provided through FormBlends-connected 503A compounding pharmacies are not FDA-approved drugs and have not undergone the same review process as brand-name products. Retatrutide is not offered as a compounded preparation through FormBlends.
Results Disclaimer. Weight loss, glucose control, and liver fat reductions cited above reflect trial averages from the Jastreboff et al. (NEJM 2023) and Rosenstock et al. (Lancet 2023) phase 2 publications. Individual results vary substantially. Trial settings include monitoring and adherence support that may not match real-world clinical use.
Trademark Notice. Ozempic, Wegovy, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Retatrutide is the international nonproprietary name for an Eli Lilly investigational compound and has no current U.S. brand name. FormBlends is not affiliated with these companies or with the sponsors of the cited research publications.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →